SLC5A2

There are 1,572 papers on SLC5A2 in aging research: 160 trials and 525 observational studies in people, 164 in animals, 30 in cells, 622 reviews. The newest story, Nov 18, 2026: “Diabetes drug class linked to fewer delirium diagnoses after surgery”.

Gene

1,572 papers study it23 findings

HGNCNCBI GeneTaxon

365 new papers in 30 daysSee all 1,572 papers on SLC5A2

At a glance

The findings reach people, from one lab or study. 10 independent labs in 8 countries; 301 trials, 65 with no results posted.

“Rare variants in SLC5A2 were associated with decreased uric acid”
Using rare coding variants in SLC5A2 to explore the impact of SGLT2 inhibitors on cardiorenal outcomesEuropean journal of preventive cardiology2026doi:10.1093/eurjpc/zwag539

None of its findings points the other way.

Cells, mice and humans: a single group. Worms or flies: nothing yet.
  • 10 independent labs in 8 countries
  • 301 trials, 65 with no results posted
  • Funders: Japan Society for the Promotion of Science and others
  • 4 of 16 findings with company ties
  • 284 of 301 trials sponsored by developers of drugs aimed at it
  • Human trial160
  • Humans525
  • Animals162
  • Model organisms2
  • Cells30
  • In silico23

Interventions

4

SGLT2 inhibitors

downin humans1

1 study
  1. SGLT2 inhibitors are linked with lower SLC5A2 in humans (valvular expression).

    “SGLT2i therapy was associated with reduced valvular expression of SGLT1/2, GLUT4, and NHE”

    Humansvalvular expressionaortic valve

    SGLT2-Inhibitors and Molecular Signatures of Aortic Valve Remodeling in Severe Aortic Stenosis: The Valve-AS Study

    JACC. Basic to translational science

More on SGLT2 inhibitors

Gamma-oryzanol

downin pig cells1

1 study
  1. Gamma-oryzanol decreases SLC5A2 in pig cells (replicative senescence of endothelial cells at P3).

    “γ-Orz suppressed sodium-glucose co-transporter 2 expression”

    Cellsreplicative senescence of endothelial cells at P3

    γ-Oryzanol Ameliorates Endothelial Replicative Senescence via Downregulation of SGLT2 Expression to Attenuate NADPH-Driven Oxidative Stress

    Biomolecules & therapeutics

More on Gamma-oryzanol

GYY4137

downin cells1

1 study
  1. GYY4137 decreases SLC5A2 in senescent endothelial cells.

    “sodium glucose transporter type 2 (SGLT2) and phosphorylation of STAT3, which could be reversed by the administration of a slow but sustained release agent of H 2S, GYY4137”

    Cellsin senescent endothelial cells

    Hydrogen sulfide ameliorates senescence in vascular endothelial cells through ameliorating inflammation and activating PPARδ/SGLT2/STAT3 signaling pathway

    Acta biochimica et biophysica Sinica

More on GYY4137

Vertical sleeve gastrectomy

downin mice1

1 study
  1. Vertical sleeve gastrectomy decreases SLC5A2 in lean and obese mice.

    “the expression of sodium-glucose cotransporter 2 (SGLT2/Slc5a2) is reduced in the kidney of lean and obese mice following vertical sleeve gastrectomy (VSG).”

    Animalsin lean and obese micekidney

    Vertical Sleeve Gastrectomy Lowers SGLT2/Slc5a2 Expression in the Mouse Kidney

    Diabetes

More on Vertical sleeve gastrectomy

Effects

6

Cellular senescence

upin human cells1upin humans1

2 studies
  1. SLC5A2 increases cellular senescence in humans (when induced by pathological stress).

    “Induced SGLT2 may amplify oxidative stress, inflammation, and senescence.”

    Reviewwhen induced by pathological stress

    SGLT2 beyond the kidney: an inducible player in endothelial dysfunction and cardiovascular diseases

    Cardiovascular diabetology

  2. SLC5A2 increases cellular senescence in human cells (shown by knockdown in high-glucose-exposed proximal tubular cells).

    “which was suppressed by knock-down of p21 or sodium glucose cotransporter (SGLT) 2.”

    Cellsshown by knockdown in high-glucose-exposed proximal tubular cells

    Hyperglycemia causes cellular senescence via a SGLT2- and p21-dependent pathway in proximal tubules in the early stage of diabetic nephropathy

    Journal of diabetes and its complications

More on Cellular senescence

Vascular calcification

mediatesin cells1

1 study
  1. SLC5A2 mediates vascular calcification in cells (dapagliflozin anti-calcification effect; SGLT2 overexpression attenuated this effect).

    “DAPA exerts its anti-calcification effects on VSMCs by directly targeting SGLT2, with the overexpression of SGLT2 being sufficient to attenuate these beneficial effects.”

    Cellsdapagliflozin anti-calcification effect; SGLT2 overexpression attenuated this effect

    Dapagliflozin targets SGLT2/SIRT1 signaling to attenuate the osteogenic transdifferentiation of vascular smooth muscle cells

    Cellular and molecular life sciences : CMLS

More on Vascular calcification

Glucose homeostasis

is required forin mice1

1 study
  1. SLC5A2 is required for glucose homeostasis in VSG-induced reduction of glucose excursions.

    “inactivation of the SGLT2/Slc5a2 gene by clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 attenuated the effects of VSG”

    Animalsin VSG-induced reduction of glucose excursions

    Vertical Sleeve Gastrectomy Lowers SGLT2/Slc5a2 Expression in the Mouse Kidney

    Diabetes

Lifespan

no changein mice1

1 study
  1. SLC5A2 showed no clear effect on lifespan in mice (spontaneous Slc5a2 mutation (SAMP10-ΔSglt2 vs SAMP10(+))).

    “No differences were found in the survival curve, depression-like behavior, and age-related brain atrophy between SAMP10-ΔSglt2 and SAMP10(+).”

    Animalsspontaneous Slc5a2 mutation (SAMP10-ΔSglt2 vs SAMP10(+))

    Mutation in Sodium-Glucose Cotransporter 2 Results in Down-Regulation of Amyloid Beta (A4) Precursor-Like Protein 1 in Young Age, Which May Lead to Poor Memory Retention in Old Age

    International journal of molecular sciences

Aplp1 expression

upin mice1

1 study
  1. SLC5A2 increases Aplp1 expression in mice (spontaneous Slc5a2 mutation (SAMP10-ΔSglt2 vs SAMP10(+))).

    “Amyloid beta (A4) precursor-like protein 1 (Aplp1) expression was significantly lower in the hippocampus of SAMP10-ΔSGLT2 than in SAMP10(+) at 2 months of age”

    Animalsspontaneous Slc5a2 mutation (SAMP10-ΔSglt2 vs SAMP10(+))hippocampus

    Mutation in Sodium-Glucose Cotransporter 2 Results in Down-Regulation of Amyloid Beta (A4) Precursor-Like Protein 1 in Young Age, Which May Lead to Poor Memory Retention in Old Age

    International journal of molecular sciences

More on Aplp1 expression

Memory retention

upin mice1

1 study
  1. SLC5A2 increases memory retention in mice (spontaneous Slc5a2 mutation (SAMP10-ΔSglt2 vs SAMP10(+))).

    “However, memory retention was lower in SAMP10-ΔSglt2 mice than SAMP10(+).”

    Animalsspontaneous Slc5a2 mutation (SAMP10-ΔSglt2 vs SAMP10(+))

    Mutation in Sodium-Glucose Cotransporter 2 Results in Down-Regulation of Amyloid Beta (A4) Precursor-Like Protein 1 in Young Age, Which May Lead to Poor Memory Retention in Old Age

    International journal of molecular sciences

Associations

12

Heart failure

downin humans1

1 study
  1. SLC5A2 is associated with heart failure in humans (Rare coding variants in participants with type 2 diabetes).

    “In patients with T2D, the rare variants within SLC5A2 were also associated with a lower probability of having heart failure”

    HumansRare coding variants in participants with type 2 diabetes

    Using rare coding variants in SLC5A2 to explore the impact of SGLT2 inhibitors on cardiorenal outcomes

    European journal of preventive cardiology

More on Heart failure

Estimated glomerular filtration rate

upin humans1

1 study
  1. SLC5A2 is associated with estimated glomerular filtration rate in humans (Rare coding variants; European ancestry participants).

    “with increased haematocrit (PCauchy = 1.67 × 10-5), haemoglobin (PCauchy = 1.60 × 10-5), and estimated glomerular filtration rate (PCauchy = 9.88 × 10-4).”

    HumansRare coding variants; European ancestry participantsn = 442,570

    Using rare coding variants in SLC5A2 to explore the impact of SGLT2 inhibitors on cardiorenal outcomes

    European journal of preventive cardiology

More on Estimated glomerular filtration rate

Hemoglobin

upin humans1

1 study
  1. SLC5A2 is associated with hemoglobin in humans (Rare coding variants; European ancestry participants).

    “Rare genetic variants in SLC5A2 were associated with increased haemoglobin and decreased uric acid.”

    HumansRare coding variants; European ancestry participantsn = 442,570

    Using rare coding variants in SLC5A2 to explore the impact of SGLT2 inhibitors on cardiorenal outcomes

    European journal of preventive cardiology

More on Hemoglobin

Uric acid

downin humans1

1 study
  1. SLC5A2 is associated with uric acid in humans (Rare coding variants; European ancestry participants).

    “Rare variants in SLC5A2 were associated with decreased uric acid”

    HumansRare coding variants; European ancestry participantsn = 442,570

    Using rare coding variants in SLC5A2 to explore the impact of SGLT2 inhibitors on cardiorenal outcomes

    European journal of preventive cardiology

More on Uric acid

Clear cell morphology

upin humans1

1 study
  1. SLC5A2 is associated with clear cell morphology in humans (paired clear cell versus eosinophilic components in VHL-deficient tumors).

    “SGLT2 immunohistochemical scores were significantly higher in clear cell components than in eosinophilic components (p = 0.026)”

    Humanspaired clear cell versus eosinophilic components in VHL-deficient tumorsclear cell renal cell carcinoman = 6

    Sodium-Glucose Cotransporter 2-Mediated Glucose Uptake Contributes to Glycogen Accumulation in Clear Cell Renal Cell Carcinoma: Implications for Clear Cell Morphology and Potential Therapeutic Relevance

    International journal of molecular sciences

Diabetic retinopathy

upin silico1OR 1.21

1 study
  1. SLC5A2 is associated with diabetic retinopathy in silico (Mendelian randomization analysis) (OR = 1.21, 95% CI 1.05-1.39).

    “MR supported an association between genetically proxied SGLT2 and DR risk (OR = 1.21, 95% CI 1.05-1.39; P = 0.009).”

    In silicoMendelian randomization analysis

    SGLT2 inhibitors and diabetic retinopathy progression: evidence from a retrospective cohort study and Mendelian randomization analysis

    Frontiers in endocrinology

More on Diabetic retinopathy

Hepatocarcinogenesis

upin humans1

1 study
  1. SLC5A2 is associated with hepatocarcinogenesis in humans.

    “upregulated SGLT2 expression may be associated with hepatocarcinogenesis and therapy resistance”

    Review

    Metabolic Concepts of Sodium-Glucose Cotransporter 2 Inhibitors-Based Therapies Against Hepatocarcinogenesis and Therapy Resistance in Hepatocellular Carcinoma

    Life (Basel, Switzerland)

More on Hepatocarcinogenesis

Metabolic dysfunction-associated steatohepatitis

upin humans1

1 study
  1. SLC5A2 is associated with metabolic dysfunction-associated steatohepatitis in humans.

    “Liver samples from subjects with NASH were associated with increased SGLT2 and O-GlcNAcylation expression compared with controls.”

    Humansliver

    Increased expression of sodium-glucose cotransporter 2 and O-GlcNAcylation in hepatocytes drives non-alcoholic steatohepatitis

    Metabolism: clinical and experimental

More on Metabolic dysfunction-associated steatohepatitis

Lifespan

mixedin mice1

1 study
  1. SLC5A2 is associated with lifespan in mice.

    “SGLT2 is not only responsible for sugar reabsorption but is also related to other functions, such as bone metabolism, longevity, and cognitive functions.”

    Review

    Mouse Models with SGLT2 Mutations: Toward Understanding the Role of SGLT2 beyond Glucose Reabsorption

    International journal of molecular sciences

Empagliflozin

mixedin silico1

1 study
  1. Empagliflozin is associated with SLC5A2 in silico (predicted by network pharmacology and molecular docking).

    “Empagliflozin may regulate the targets of SLC5A2, SLC5A1, LDHA, KLK1, KLF5, and GSTP1.”

    In silicopredicted by network pharmacology and molecular docking

    Identification of key genes, biological functions, and pathways of empagliflozin by network pharmacology and its significance in the treatment of type 2 diabetes mellitus

    Annals of translational medicine

More on Empagliflozin

All 12

Latest

Dec 2025: 48Jan 2026: 106Feb 2026: 98Mar 2026: 98Apr 2026: 16May 2026: 21Jun 2026: 37Jul 2026: 60Aug 2026: 89Sep 2026: 96Oct 2026: 240Nov 2026: 1411,050 papers in 12 months
BMC Geriatrics

Diabetes drug class linked to fewer delirium diagnoses after surgery

Delirium diagnoses within seven days of major surgery occurred in 3.98% of older patients with type 2 diabetes prescribed the drugs, versus 4.53% of matched patients…Delirium diagnoses within seven days of major surgery occurred in 3.98% of older patients with type 2 diabetes prescribed the drugs, versus 4.53% of matched patients without prescriptions.

Cohort · 126,190 peoplePostoperative delirium

See all 1,572 papers on SLC5A2